Successful Treatment of Persistent Symptomatic Coronavirus Disease 19 Infection With Extended-Duration Nirmatrelvir-Ritonavir Among Outpatients With Hematologic Cancer
Catherine Liu, Leah H Yoke, Pooja Bhattacharyya, Ryan D. Cassaday, Guang‐Shing Cheng, Zahra Kassamali Escobar, Cristina Maria Ghiuzeli, Denise J. McCulloch, Steven A. Pergam, Pavitra Roychoudhury, Frank Tverdek, Joshua T. Schiffer, Emily S. Ford
Abstract
Persistent symptomatic coronavirus disease 2019 (COVID-19) is a distinct clinical entity among patients with hematologic cancer and/or profound immunosuppression. The optimal medical management is unknown. We describe 2 patients who had symptomatic COVID-19 for almost 6 months and were successfully treated in the ambulatory setting with extended courses of nirmatrelvir-ritonavir.
Topics & Concepts
MedicineRitonavirCoronavirus disease 2019 (COVID-19)ImmunosuppressionMalignancyHematologic malignancyInternal medicineAmbulatoryDiseaseHuman immunodeficiency virus (HIV)ImmunologyInfectious disease (medical specialty)Viral loadAntiretroviral therapyCOVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 ResearchCOVID-19 and healthcare impacts